Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00866294
First received: March 19, 2009
Last updated: May 29, 2014
Last verified: February 2013
  Purpose

This is a randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy of controlled-release (CR) formulation of paroxetine orally administered to patients with major depressive disorder (MDD) at a dose level in the range of 25 - 50 mg/day (initial dose level, 12.5 or 25 mg/day) once daily after evening meal for 8 weeks based on the decrease in HAM-D (Hamilton Depression Rating Scale) total score, to evaluate the safety based on adverse events, laboratory data and vital signs, and to describe the efficacy and safety of immediate release (IR) formulation of paroxetine.


Condition Intervention Phase
Depressive Disorder
Drug: paroxetine IR 10mg tablet
Drug: paroxetine IR 20mg tablet
Drug: matched placebo to paroxetine IR 10mg or 20mg
Drug: Paroxetine CR 12.5mg tablet
Drug: Paroxetine CR 25mg tablet
Drug: matched placebo to paroxetine CR 12.5mg or 25mg
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Controlled Release Paroxetine in the Treatment of Major Depressive Disorder

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Adjusted Mean Change From Baseline in the Hamilton Depression Rating Scale (HAM-D; 17 Items) Total Score at Week 8 [ Time Frame: Baseline (Week 0) and Week 8 ] [ Designated as safety issue: No ]
    The HAM-D measures the severity of depressive symptoms in participants with major depressive disorder (MDD). It is a checklist of 17 items that are ranked on a scale of 0-4 or 0-2. The range for the total score (which is the sum of the scores of all 17 items) is 0-52; a higher score indicates greater severity of symptoms. Mean change from baseline was calculated as the value at Week 8 minus the Baseline value.


Secondary Outcome Measures:
  • Mean Change From Baseline in the HAM-D Total Score at Weeks 1, 2, 3, 4, 6, and 8 [ Time Frame: Baseline (Week 0); Weeks 1, 2, 3, 4, 6, and 8 ] [ Designated as safety issue: No ]
    The HAM-D measures the severity of depressive symptoms in participants with MDD. It is a checklist of 17 items that are ranked on a scale of 0-4 or 0-2. The range for the total score (which is the sum of the scores of all 17 items) is 0-52; a higher score indicates greater severity of symptoms. Mean change from baseline was calculated as the value at each time point minus the Baseline value.

  • Percentage of HAM-D Responders at Weeks 4 and 8 [ Time Frame: Weeks 4 and 8 ] [ Designated as safety issue: No ]
    The HAM-D measures the severity of depressive symptoms in participants with MDD. It is a checklist of 17 items that are ranked on a scale of 0-4 or 0-2. The range for the total score (which is a sum of the scores of all 17 items) is 0-52; a higher score indicates greater severity of symptoms. Responders are defined as participants with a 50 percent or greater reduction from baseline in the HAM-D total score.

  • Percentage of HAM-D Remitters at Weeks 4 and 8 [ Time Frame: Weeks 4 and 8 ] [ Designated as safety issue: No ]
    The HAM-D measures the severity of depressive symptoms in participants with MDD. It is a checklist of 17 items that are ranked on a scale of 0-4 or 0-2. The range for the total score (which is the sum of the scores of all 17 items) is 0-52; a higher score indicates greater severity of symptoms. Remitters are defined as participants with a HAM-D total score of 7 or less.

  • Mean Change From Baseline in the Clinical Global Impression-Severity of Illness (CGI-SI) Scores at Weeks 1, 2, 3, 4, 6, and 8 [ Time Frame: Baseline (Week 0); Weeks 1, 2, 3, 4, 6, and 8 ] [ Designated as safety issue: No ]
    The 7-point CGI-SI scale assesses the clinician's impression of the participant's current illness state. Scores on the CGI-SI range from 1 = not ill at all to 7 = among the most extremely ill. Mean change from baseline was calculated as the value at each time point minus the baseline value.

  • Percentage of Responders Based on the Clinical Global Impression-Global Improvement (CGI-GI) Scores at Weeks 4 and 8 [ Time Frame: Weeks 4 and 8 ] [ Designated as safety issue: No ]
    The 7-point CGI-GI assesses the participant's improvement or worsening from baseline. Scores on the CGI-GI range from 1 = very much improved to 7 = very much worse. Responders are defined as participants with a score of 1 or 2 = much improved.


Enrollment: 416
Study Start Date: April 2009
Study Completion Date: February 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: paroxetine CR group
controlled-release (CR) of paroxetine 12.5 to 50mg/day
Drug: matched placebo to paroxetine IR 10mg or 20mg
1 or 2 tablets once a day
Drug: Paroxetine CR 12.5mg tablet
1 or 2 tablets once a day
Drug: Paroxetine CR 25mg tablet
1 or 2 tablets once a day
Drug: matched placebo to paroxetine CR 12.5mg or 25mg
1 or 2 tablets once a day
paroxetine IR group
Immediate-release (IR) of paroxetine 10 to 40mg/day as a reference arm
Drug: paroxetine IR 10mg tablet
1 or 2 tablets once a day
Drug: paroxetine IR 20mg tablet
1 tablet once a day
Drug: matched placebo to paroxetine IR 10mg or 20mg
1 or 2 tablets once a day
Drug: matched placebo to paroxetine CR 12.5mg or 25mg
1 or 2 tablets once a day
Placebo Comparator: placebo group
matched placebo to both paroxetine CR and paroxetine IR
Drug: matched placebo to paroxetine IR 10mg or 20mg
1 or 2 tablets once a day
Drug: matched placebo to paroxetine CR 12.5mg or 25mg
1 or 2 tablets once a day

  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

<at the start of placebo run-in phase> Only the patients who meet all of the following conditions at Week -1 (at the start of placebo run-in phase) will be enrolled in this study. The hospitalization status will be no object. and Gender: No object.

  • Target disease: Patients diagnosed as having one of the following depressive disorders based on DSM-IV-TR classification in conjunction with M.I.N.I. (The Mini International Neuropsychiatric Interview, Japanese version 5.0.0. [2003]) and showing currently a symptom of depression or depressed sate
  • Major depressive disorder, single episode (296.2) (excluding those accompanied by comorbid psychiatric disorders)
  • Major depressive disorder, recurrent (296.3) (excluding those accompanied by comorbid psychiatric disorders)
  • Age: >= 20 years (at the time of obtaining consent)
  • Consent: Patients from whom written consent to participate in this study can be obtained
  • Gender:
  • Female patients of childbearing potential can be enrolled. But, such patients who can be enrolled are limited to only those who are negative in the pregnancy test performed at the start of the placebo run-in phase and who agree to receive a pregnancy test at the time point defined in the study period and surely perform any of the contraceptive methods.
  • Male subjects must abstain from (or use a condom during) sexual intercourse with a pregnant or lactating female. Male subjects must abstain from or use a condom plus spermicidal agent (foam/gel/film/cream/suppository) during sexual intercourse with a female of child-bearing potential.
  • Patients whose HAM-D (17 items) total score is >= 20 points
  • Patients whose duration of current episode at least 12 weeks but no longer than 24 months
  • Patients whose score of "depressed mood" (HAM-D Item 1) is >= 2 points
  • QTc<450 millisecond (msec) or <480 msec for patients with Bundle Branch Block - values based on either single ECG values or triplicate ECG averaged QTc values obtained over a brief recording period.

For the purposes of these criteria, QTc B (Bazett's correction) is defined as (QT interval [msec]) /(square root of RR interval [seconds])

<at the start of treatment phase> Only the patients who meet all of the following conditions at Week -1 (at the start of the placebo run-in phase) and Week 0 (at the start of treatment phase) can be shifted to the treatment phase.

  • Patients whose HAM-D (17 items) total score is >=20 points
  • Patients whose score of "depressed mood" (HAM-D Item 1) is >=2 points

Exclusion Criteria:

<at the start of placebo run-in phase> The patients who are meeting any of the following conditions at Week -1 (at the start of placebo run-in phase) must not be enrolled in this study.

  • Patients whose primary diagnosis is a disorder classified to Axis I other than major depressive disorder in DSM-IV-TR classification (dysthymic disorder, eating disorder, specific phobia (monophobia), posttraumatic stress disorder, obsessive-compulsive disorder, panic disorder, etc.)
  • Patients with a current DSM-IV-TR Axis II diagnosis that suggested non-responsiveness to pharmacotherapy or non- compliance with the protocol (e.g., antisocial or borderline personality disorder)
  • Patients with a history or complication of another (non-MDD) mental disorder (schizophrenia, etc.)
  • Patients with a history or complication of manic episodes
  • Patients diagnosed as having an attentional deficit disorder or hyperactivity disorder
  • Patients diagnosed as having a pervasive development disorder or mental retardation
  • Patients diagnosed as abusing or dependent on alcohol or drug within one year before the Week -1 visit
  • Patients who have undergone electroconvulsive therapy within one year before the Week -1 visit for the treatment of the current episode
  • Patients who have a history of treatment with depot neuroleptics
  • Patients with a history of serotonin syndrome or neuroleptic malignant syndrome
  • Patients with a >= 3-point score of "suicide" (HAM-D Item 3) or patients whose Columbia Suicide Severity Rating Scale (C-SSRS) assessment suggests that they are or have been at significant risk for harming themselves or have actually harmed themselves, or who, in the opinion of the investigator (subinvestigator), are at significant risk for harming self or others.
  • Patients with a history of suicide attempt, self-injurious action (excluding action with no intention of suicide) or overdosage (excluding apparently accidental overdosage)
  • Patients who have taken another investigational product or a drug used in a post-marketing clinical study within 12 weeks before the Week -1 visit
  • Patients with glaucoma
  • Patients with a convulsive disorder such as epilepsy or a history of it
  • Patients using a drug increasing an onset risk of bleeding, patients with a bleeding tendency or bleeding diathesis
  • Patients complicated with severe renal or hepatic dysfunction
  • Patients complicated with serious organic brain disorder
  • Patients with a history or complication of cancer or malignant tumor
  • Patients complicated by chronic hepatitis B or C being positive in test of hepatitis B surface antigen (HbsAg) or hepatitis C antibody
  • Pregnant, lactating or possibly pregnant female patients, and female patients wishing to be pregnant during the study period
  • Patients who have previously been unresponsive to paroxetine therapy (e.g. >4wks unresponsive to paroxetine for depression).
  • Patients with a history of having discontinued treatment due to an adverse event caused by paroxetine
  • Patients with a history of hypersensitivity to paroxetine.
  • Patients judged ineligible to participate in this study by the investigator or subinvestigator

Exclusion criteria < at the start of treatment phase> The patients who are meeting any of the following conditions at Week 0 (at the start of treatment phase) must not be allowed to the treatment phase.

  • Patients with a 3 or more-point score of "suicide" (HAM-D Item 3) or with a strong suicidal tendency by C-SSRS and investigator clinical judgement.
  • Patients whose HAM-D (17 items) total score at the Week 0 visit has changed ±25 %, or exceeding the range of ±25 % of the score at the Week -1 visit
  • Patients whose Drug 1 (run-in placebo) compliance rate in the period from Week -1 to Week 0 has been < 80 %
  • Patients judged ineligible as the study subjects by the investigator or subinvestigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00866294

  Show 67 Study Locations
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided by GlaxoSmithKline

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00866294     History of Changes
Other Study ID Numbers: 112810
Study First Received: March 19, 2009
Results First Received: October 14, 2010
Last Updated: May 29, 2014
Health Authority: Japan: Ministry of Health, Labor and Welfare
South Korea: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
Immediate-release formulation of paroxetine (paroxetine IR)
HAM-D (17 items)
Controlled-release formulation of paroxetine (paroxetine CR)

Additional relevant MeSH terms:
Depressive Disorder
Depression
Depressive Disorder, Major
Disease
Mood Disorders
Mental Disorders
Behavioral Symptoms
Pathologic Processes
Paroxetine
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 01, 2014